Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

Similar articles for PubMed (Select 22461615)

1.

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.

Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA.

Science. 2012 Mar 30;335(6076):1638-43. doi: 10.1126/science.1215135.

2.

mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8.

Kim SJ, DeStefano MA, Oh WJ, Wu CC, Vega-Cotto NM, Finlan M, Liu D, Su B, Jacinto E.

Mol Cell. 2012 Dec 28;48(6):875-87. doi: 10.1016/j.molcel.2012.09.029. Epub 2012 Nov 8.

3.

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.

Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA.

Mol Cell Biol. 2009 Mar;29(6):1411-20. doi: 10.1128/MCB.00782-08. Epub 2008 Dec 29.

4.

Dissecting mammalian target of rapamycin to promote longevity.

Mendelsohn AR, Larrick JW.

Rejuvenation Res. 2012 Jun;15(3):334-7. doi: 10.1089/rej.2012.1347. Review.

PMID:
22758368
5.

Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan.

Lamming DW, Mihaylova MM, Katajisto P, Baar EL, Yilmaz OH, Hutchins A, Gultekin Y, Gaither R, Sabatini DM.

Aging Cell. 2014 Oct;13(5):911-7. doi: 10.1111/acel.12256. Epub 2014 Jul 25.

6.

Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.

Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A, Maeder C, Fournier M, Montet X, Rohner-Jeanrenaud F, Foti M.

Br J Pharmacol. 2012 Apr;165(7):2325-40. doi: 10.1111/j.1476-5381.2011.01716.x.

7.

mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.

Le Bacquer O, Queniat G, Gmyr V, Kerr-Conte J, Lefebvre B, Pattou F.

J Endocrinol. 2013 Jan 2;216(1):21-9. doi: 10.1530/JOE-12-0351. Print 2013 Jan.

8.

Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium.

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Cell Death Dis. 2014 May 8;5:e1214. doi: 10.1038/cddis.2014.178.

9.

Sestrin 3 protein enhances hepatic insulin sensitivity by direct activation of the mTORC2-Akt signaling.

Tao R, Xiong X, Liangpunsakul S, Dong XC.

Diabetes. 2015 Apr;64(4):1211-23. doi: 10.2337/db14-0539. Epub 2014 Nov 5.

PMID:
25377878
10.

Ceramide inhibits insulin-stimulated Akt phosphorylation through activation of Rheb/mTORC1/S6K signaling in skeletal muscle.

Hsieh CT, Chuang JH, Yang WC, Yin Y, Lin Y.

Cell Signal. 2014 Jul;26(7):1400-8. doi: 10.1016/j.cellsig.2014.03.004. Epub 2014 Mar 17.

PMID:
24650522
11.

Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism.

Kumar A, Lawrence JC Jr, Jung DY, Ko HJ, Keller SR, Kim JK, Magnuson MA, Harris TE.

Diabetes. 2010 Jun;59(6):1397-406. doi: 10.2337/db09-1061. Epub 2010 Mar 23.

12.

Acute rapamycin treatment improved glucose tolerance through inhibition of hepatic gluconeogenesis in rainbow trout (Oncorhynchus mykiss).

Dai W, Panserat S, Terrier F, Seiliez I, Skiba-Cassy S.

Am J Physiol Regul Integr Comp Physiol. 2014 Nov 15;307(10):R1231-8. doi: 10.1152/ajpregu.00166.2014. Epub 2014 Aug 27.

PMID:
25163922
13.

Rapamycin regulates the phosphorylation of rictor.

Akcakanat A, Singh G, Hung MC, Meric-Bernstam F.

Biochem Biophys Res Commun. 2007 Oct 19;362(2):330-3. Epub 2007 Aug 8.

14.

Grb10 promotes lipolysis and thermogenesis by phosphorylation-dependent feedback inhibition of mTORC1.

Liu M, Bai J, He S, Villarreal R, Hu D, Zhang C, Yang X, Liang H, Slaga TJ, Yu Y, Zhou Z, Blenis J, Scherer PE, Dong LQ, Liu F.

Cell Metab. 2014 Jun 3;19(6):967-80. doi: 10.1016/j.cmet.2014.03.018. Epub 2014 Apr 17.

15.

Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.

Houde VP, Brûlé S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, Marette A.

Diabetes. 2010 Jun;59(6):1338-48. doi: 10.2337/db09-1324. Epub 2010 Mar 18.

16.

Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.

Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M.

Int J Oncol. 2009 Oct;35(4):731-40.

PMID:
19724909
17.

Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice.

Makki K, Taront S, Molendi-Coste O, Bouchaert E, Neve B, Eury E, Lobbens S, Labalette M, Duez H, Staels B, Dombrowicz D, Froguel P, Wolowczuk I.

PLoS One. 2014 Apr 7;9(4):e92684. doi: 10.1371/journal.pone.0092684. eCollection 2014.

18.

Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability.

Pajvani UB, Qiang L, Kangsamaksin T, Kitajewski J, Ginsberg HN, Accili D.

Nat Med. 2013 Aug;19(8):1054-60. doi: 10.1038/nm.3259. Epub 2013 Jul 7.

19.

Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive.

Lamming DW, Ye L, Astle CM, Baur JA, Sabatini DM, Harrison DE.

Aging Cell. 2013 Aug;12(4):712-8. doi: 10.1111/acel.12097. Epub 2013 Jun 7.

20.

Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice.

Tripathy S, Jump DB.

J Lipid Res. 2013 Jan;54(1):71-84. doi: 10.1194/jlr.M028787. Epub 2012 Oct 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk